CN105194072A - Traditional Chinese medicine composition with efficacy of assisting in treatment of pulmonary infection - Google Patents
Traditional Chinese medicine composition with efficacy of assisting in treatment of pulmonary infection Download PDFInfo
- Publication number
- CN105194072A CN105194072A CN201510742181.XA CN201510742181A CN105194072A CN 105194072 A CN105194072 A CN 105194072A CN 201510742181 A CN201510742181 A CN 201510742181A CN 105194072 A CN105194072 A CN 105194072A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- blood
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention applies to anti-infection adjunctive treatment of the lung of a patient suffering from AECOPD (acute exacerbation chronic obstructive pulmonary disease) complicated by pulmonary hypertension and discloses traditional Chinese medicine composition with efficacy of assisting in treatment of pulmonary infection. The traditional Chinese medicine composition comprises raw materials in parts by weight as follows: 600-1,200 parts of Chinese angelica, 600-1,200 parts of dried rehmannia, 900-1,500 parts of peach kernels, 600-1,200 parts of safflower, 400-800 parts of bitter oranges, 400-800 parts of red paeony roots, 100-500 parts of radix bupleuri, 100-500 parts of liquorice, 200-600 parts of platycodon roots, 200-600 parts of rhizoma chuanxiong and 700-1,200 parts of achyranthes bidentata. The Chinese angelica, the dried rehmannia, the peach kernels, the safflower, the red paeony roots and the rhizoma chuanxiong can activate the blood, remove blood stasis, nourish blood and prevent vital qi damage caused by pure removal of blood stasis; immature bitter orange, the radix bupleuri and the liquorice promote circulation of liver energy, and blood circulation is promoted after the liver energy circulation is promoted; the platycodon roots are added, the traditional Chinese medicine composition is guided to move up to the blood house of the chest; the achyranthes bidentata promotes downward movement of static blood, and accordingly, blood circulation is promoted. The traditional Chinese medicine composition can well assist antibiotic in treatment of pulmonary infection based on AECOPD complicated by pulmonary hypertension.
Description
Technical field
The invention belongs to the field that Chinese Traditional Medicine is applied in critical care medicine, is especially pulmonary's infection auxiliary treatment that Hospitalized Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease (hereinafter referred to as AECOPD) merges patients with pulmonary hypertension at underlying diseases.
Background technology
Pulmonary hypertension is the key factor that the clinical course caused worsens, and the pulmonary infection on AECOPD pulmonary hypertension basis, cause the major incentive of death often.To the treatment of this kind of pulmonary infection, because patient is many with other system complication, the simple therapeutic effect using antibiotic anti-infection effect often not reach clinician's satisfaction.
Summary of the invention
The technical problem that invention solves
By applying traditional theory of Chinese medical science and composition principle, enhancing the therapeutic effect in the pulmonary infection that antibiotic occurs on AECOPD pulmonary hypertension basis well, thus extending cure rate and the life span of patient.
The technical scheme adopted
Have the Chinese medicine composition of auxiliary treatment pulmonary infection effect, said composition is made up of the crude drug of following weight ratio: Radix Angelicae Sinensis 600-1200 part, Radix Rehmanniae 600-1200 part, Semen Persicae 900-1500 part, Flos Carthami 600-1200 part, Fructus Aurantii 400-800 part, Radix Paeoniae Rubra 400-800 part, Radix Bupleuri 100-500 part, Radix Glycyrrhizae 100-500 part, Radix Platycodonis 200-600 part, Rhizoma Chuanxiong 200-600 part, Radix Achyranthis Bidentatae 700-1200 part.
Further, the consisting of of crude drug: Radix Angelicae Sinensis 700-1000 part, Radix Rehmanniae 800-1100 part, Semen Persicae 1000-1400 part, Flos Carthami 800-1100 part, Fructus Aurantii 500-700 part, Radix Paeoniae Rubra 500-700 part, Radix Bupleuri 200-400 part, Radix Glycyrrhizae 200-400 part, Radix Platycodonis 300-500 part, Rhizoma Chuanxiong 300-550 part, Radix Achyranthis Bidentatae 800-1100 part.
Further, the consisting of of crude drug: Radix Angelicae Sinensis 900 parts, 900 parts, the Radix Rehmanniae, 1200 parts, Semen Persicae, 900 parts, Flos Carthami, Fructus Aurantii 600 parts, Radix Paeoniae Rubra 600 parts, Radix Bupleuri 300 parts, 300 parts, Radix Glycyrrhizae, Radix Platycodonis 450 parts, Rhizoma Chuanxiong 450 parts, Radix Achyranthis Bidentatae 1000 parts.
Radix Angelicae Sinensis in we, the Radix Rehmanniae, Semen Persicae, Flos Carthami, Radix Paeoniae Rubra, Rhizoma Chuanxiong blood circulation promoting and blood stasis dispelling and nourishing blood, the wound of the anti-purification stasis of blood is just; Irritability unclogged and readjusted by Fructus Aurantii Immaturus, Radix Bupleuri, Radix Glycyrrhizae, makes the capable then blood of gas; Add that Radix Platycodonis priming is up to be reached in blood mansion in the heart; Radix Achyranthis Bidentatae draws the descending and promoting blood circulation of blood stasis.All medicines are harmonious, and form the agent of vital energy regualting and blood circulation-promoting.We are not just hindering with blood circulation promoting and blood stasis dispelling, depressed liver-energy dispersing and QI regulating and do not consume gas for feature, reach effect that fortune is invigorated blood circulation, thus auxiliary antibiosis is usually treated AECOPD and merged pulmonary infection on pulmonary hypertension basis.
Beneficial effect
Carry out research to Chinese medicine composition of the present invention to show: after applying Chinese medicine composition of the present invention, before and after heart, load alleviates, left ventricular ejection fraction improves, pulmonary edema alleviates thus the disperse of oxygen improves, to strengthen antibiotic anti-infection effect.Chinese medicine composition of the present invention, while auxiliary treatment control AECOPD merges the pulmonary infection on pulmonary hypertension basis, also has the good effect shortening the antibiotic usage course for the treatment of.
Detailed description of the invention
One, data and method:
1. collection of data
The AECOPD that collection 2013-8 to 2015-8 year the court emergency ICU is accepted for medical treatment merges pulmonary infection patient with severe symptoms 40 example that pulmonary hypertension basis occurs, be divided into two groups at random, namely while application infection Western medicine, use Chinese medicine composition auxiliary treatment group (hereinafter referred to as treatment group) of the present invention and simple western medicine treatment group (hereinafter referred to as matched group).Treatment group, on the basis using western medicine, adds or stomach note 2 times/day oral with Chinese medicine composition of the present invention, each 50ml; Matched group patient only gives simple western medicine anti-infective therapy.
1.1 diagnostic criteria
1. Western medicine diagnose standard: 2011 editions " chronic obstructive pulmonary disease diagnosis and treatment specifications " printing and distributing with reference to general office of Ministry of Health of the People's Republic of China, is diagnosed as the pulmonary infection on chronic obstructive pulmonary disease merging pulmonary hypertension basis.
2. Standards of Chinese Medical Syndrome Differentiation: with reference to State Administration of Traditional Chinese Medicine's " chronic obstructive pulmonary disease Chinese traditional medical diagnose guide " 2011 revised editions, dialectical is obstruction by phlegm card, and formulates standards of grading voluntarily.Primary symptom: cough, yellow sputum, pant, generate heat, body of the tongue is dark violet, yellow fur is thick or greasy, slippery and rapid pulse; Secondary disease: thirsty, constipation.
Table 1: TCM syndrome standards of grading
1.2 inclusive criterias: meet primary disease Western medicine diagnose standard and Syndrome Differentiation of Traditional Chinese Medicine; Merge pulmonary hypertension (finding through breast CT or Color Sonography inspection); Pulmonary infection; Need noinvasive or Mechanical ventilation.
1.3 exclusion standards: the age is less than 18 years old and is greater than 85 years old; Merge serious Liver and kidney function incomplete; Pulmonary infarction; Myocardial infarction medical history; Severe pulmonary fibrosis.
2 Therapeutic Method
2.1 medicine forms: each 9 grams of Radix Angelicae Sinensis, the Radix Rehmanniae, 12 grams, Semen Persicae, 9 grams, Flos Carthami, Fructus Aurantii, each 6 grams of Radix Paeoniae Rubra, Radix Bupleuri 3 grams, 3 grams, Radix Glycyrrhizae, Radix Platycodonis 4.5 grams, Rhizoma Chuanxiong 4.5 grams, Radix Achyranthis Bidentatae 10 grams.
2.2 make decoction by my institute's decoction room according to the standard operating procedure of operation and the program of quality control.
2.3 liang of group patients all give antibiotic, Neulized inhalation bronchodilator, glucocorticoid and the conventional therapy such as to reduce phlegm, diagnosis and treatment standard was with reference to community acquired pneumonia (CommunityAcquiredPneumonia, CAP) Consensus of experts Normalization rule antibiotic in 2011.Treatment group patient increases and gives Chinese medicine composition of the present invention oral or nasal feeding on matched group conventional western medicine treatment basis.The instructions of taking of Chinese medicine composition of the present invention is divide morning and afternoon twice clothes after decocting, each 50ml.Matched group only gives conventional therapy.Treat observe the curative effect after 7 days.
3. observation index,
3.1 be admitted to hospital after give biochemical indicator such as cardiac monitoring monitoring vital sign, arterial blood gas analysis, hepatic and renal function etc.
3.2 are admitted to hospital 24 hours expert's breast CT, Color Sonography inspection.
3.3 the 0th, 3,7 days and before leaving hospital sxemiquantitative Sputum culturing evaluate bacterial load.
3.4 the 0th, 3,7 days and before leaving hospital, look into a blood coagulation complete set.
3.5 pulmonary infection control window (PICW):
The criterion of PICW:
Amount of expectoration comparatively before obviously reduce, expectorant color turns white or shoals, and viscosity reduces and below II degree;
(2) simultaneously at least with 1 in following indication:
1. WBC≤10 × 10
9/ L or comparatively front decline>=2 × 10
9/ L;
2. body temperature comparatively before decline and lower than 38 DEG C.
(3) iconography display bronchus-pulmonary infection shadow is comparatively front obviously absorbs, and nothing is fusion patch shadow obviously.2 are met in above 3.
4. analysis and statistics
Adopt SPSS16.0 statistical software analyzing and processing data, measurement data is with mean ± standard deviation
represent, compare between two groups and adopt t inspection, compare between enumeration data group and adopt χ
2inspection.Compare two groups of patient's TCM syndrome evaluations (standards of grading are in table 1), antibiotic usage time, Mechanical ventilation time, hospital stays, superinfection incidence rates and respectively organize the difference of the index such as Fibrinogen, D dimer.P<0.05 is that difference has statistical significance.
Two, result:
Two groups of patient baseline's levels compare
2.1. two groups of patients are in age, sex, merging disease, TCM syndrome scoring, PaCO when being admitted to hospital
2dividing potential drop, oxygenation index aspect no significant difference (P>0.05), in table 2.
Table 2: two groups of patient admits's base line data
Note: two groups of baseline values are respectively organized data and compared there was no significant difference, the equal > 0.05 of P.
2.2 liang of group curative effect index:
Treatment group and matched group the antibiotic usage time, the infection control window time (my god), there is significant difference (P<0.05) in Mechanical ventilation time; But two groups in hospital stays, superinfection incidence rate without statistics difference (P>0.05).In table 3.
Table 3: the observed result of two groups of patient clinical index of assessment of curative effects
Before and after 2.3 liang of group treatments, Score index compares:
After two groups of treatments, TCM syndrome evaluation comparatively treats front decline, and between two groups, TCM syndrome evaluation treatment is better than matched group, and difference has statistical significance (P<0.05); Treatment group Fibrinogen has statistics difference before the treatment afterwards, not statistically significant before and after treatment of control group; D dimer two groups is rear all zero differences before the treatment.In table 4.
Table 4: the change of scoring aspect before and after two groups of patient treatments
Note: treatment group compares after the treatment with contrasting,
★ ★p<0.01,
★p<0.05.
Three, discuss:
This research shows, Chinese medicine composition auxiliary treatment AECOPD of the present invention is used to merge compared with pulmonary hypertension patient pulmonary infection treats aforementioned pulmonary infection with simple western medicine, TCM syndrome evaluation obviously declines, and treatment group before the treatment afterwards this score value also have significant difference.In antibiotic usage time, infection control window time, Mechanical ventilation time, compare for two groups and there is significant difference.But two groups in hospital stays, superinfection incidence rate without statistics difference.The pulmonary infection patient that this research shows to use Chinese medicine composition auxiliary treatment AECOPD of the present invention to merge pulmonary hypertension comparatively simple western medicine treatment compares, and obviously shortens antibiotic usage time and Mechanical ventilation time.
AECOPD merges the common cause of pulmonary hypertension acute exacerbation for infecting.According to theory of Chinese medical science, chronic Pulmonary Hypertension in COPD Patients Chinese medical discrimination belongs to pulmonary distension category, and pulmonary distension is many because breathing with cough with the passing of time, impaired depurative descending of lung QI, the turbid retention of expectorant, the strongly fragrant numbness of lung qi, prolonged illness can not regulate the operation of cardiopulmonary blood, and QI-blood circulation is not smooth, congestion internal resistance, congestion internal resistance bringing about the spread of body fluid runs not smooth, impels the turbid interior life of expectorant, becomes obstruction by phlegm eventually.With TAOHONG SIWU TANG Semen Persicae, Flos Carthami, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the Radix Rehmanniae, Radix Paeoniae Rubra blood circulation promoting and blood stasis dispelling and nourishing blood in Chinese medicine composition object space of the present invention, the wound of the anti-purification stasis of blood just; Radix Bupleuri, Fructus Aurantii, Radix Glycyrrhizae, Radix Paeoniae Rubra fall apart and unclog and readjust irritability, make the capable then blood of gas; Add that Radix Platycodonis priming is up to be reached in the heart (blood mansion); Radix Achyranthis Bidentatae draws the descending and promoting blood circulation of blood stasis.All medicines are harmonious, and form the agent of vital energy regualting and blood circulation-promoting.We are not just hindering with blood circulation promoting and blood stasis dispelling, depressed liver-energy dispersing and QI regulating and do not consume gas for feature, reach effect that fortune is invigorated blood circulation.Explain from modern medicine, Chinese medicine composition of the present invention is by improving alveolar, interstitial and bronchiolar microcirculation, on the one hand anti-infectives local tissue concentration is raised further, contribute to improving lung tissue local resistance on the other hand and comprise the elevate cellular reparation of secretory IgA concentration and speeding of split speed, thus strengthen infection effect, pulmonary infection control window is occurred in advance, and then effectively shortens antibiotic usage time and Patients with Mechanical Ventilation time.
Find in Chinese medicine composition of the present invention is studied further, by detection fibers proteinogen, treatment group before the treatment rear fibrinogen level has significant difference, and Fibrinogen is a kind of acute phase protein, during inflammatory reaction, Fibrinogen section obviously raises, and is one of Inflammation Marker.Further research finds, Chinese medicine composition of the present invention can improve the TNF-α of Patients with Lung Contusion, IL-6 level, thus reduces the inflammatory reaction of Patients with Lung Contusion.The theory of Chinese medicine thinks that the core pathogenesis of body pulmonary infection is volt in positive QI-insufficiency, evil poison, and clinical manifestation is simulataneous insufficiency and excessive, and deficiency of qi and blood, functional activity of QI being not smooth are this, and blood stasis, expectorant are solidifying, damp and hot to be mingled with for mark; The research of Chinese medicine also thinks that pyemic important pathologic basis accumulates in malicious heresy, blood stasis is the result of accumulateing in malicious heresy, and ascending the clear and descending the turbid is answered in treatment, regulates serum inflammatory cytokine levels, thus regulate the poised state between the proinflammatory and anti-inflammatory response of sepsis, alleviate pyemic systemic inflammatory response.Up-to-date research also finds that Chinese medicine composition of the present invention also has the action effect regulating inflammatory reaction, thus reduces the risk of microthrombusis.
Claims (3)
1. there is the Chinese medicine composition of auxiliary treatment pulmonary infection effect, it is characterized by said composition and be made up of the crude drug of following weight ratio: Radix Angelicae Sinensis 600-1200 part, Radix Rehmanniae 600-1200 part, Semen Persicae 900-1500 part, Flos Carthami 600-1200 part, Fructus Aurantii 400-800 part, Radix Paeoniae Rubra 400-800 part, Radix Bupleuri 100-500 part, Radix Glycyrrhizae 100-500 part, Radix Platycodonis 200-600 part, Rhizoma Chuanxiong 200-600 part, Radix Achyranthis Bidentatae 700-1200 part.
2. a kind of Chinese medicine composition with auxiliary treatment pulmonary infection effect as claimed in claim 1, is characterized by consisting of of crude drug: Radix Angelicae Sinensis 700-1000 part, Radix Rehmanniae 800-1100 part, Semen Persicae 1000-1400 part, Flos Carthami 800-1100 part, Fructus Aurantii 500-700 part, Radix Paeoniae Rubra 500-700 part, Radix Bupleuri 200-400 part, Radix Glycyrrhizae 200-400 part, Radix Platycodonis 300-500 part, Rhizoma Chuanxiong 300-550 part, Radix Achyranthis Bidentatae 800-1100 part.
3. a kind of Chinese medicine composition with auxiliary treatment pulmonary infection effect as claimed in claim 1, is characterized by consisting of of crude drug: Radix Angelicae Sinensis 900 parts, 900 parts, the Radix Rehmanniae, 1200 parts, Semen Persicae, 900 parts, Flos Carthami, Fructus Aurantii 600 parts, Radix Paeoniae Rubra 600 parts, Radix Bupleuri 300 parts, 300 parts, Radix Glycyrrhizae, Radix Platycodonis 450 parts, Rhizoma Chuanxiong 450 parts, Radix Achyranthis Bidentatae 1000 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510742181.XA CN105194072A (en) | 2015-11-04 | 2015-11-04 | Traditional Chinese medicine composition with efficacy of assisting in treatment of pulmonary infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510742181.XA CN105194072A (en) | 2015-11-04 | 2015-11-04 | Traditional Chinese medicine composition with efficacy of assisting in treatment of pulmonary infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105194072A true CN105194072A (en) | 2015-12-30 |
Family
ID=54942257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510742181.XA Pending CN105194072A (en) | 2015-11-04 | 2015-11-04 | Traditional Chinese medicine composition with efficacy of assisting in treatment of pulmonary infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105194072A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114514912A (en) * | 2022-03-10 | 2022-05-20 | 北京中医药大学第三附属医院 | Construction method of LPS-induced chronic lung injury stagnant heat internal accumulation syndrome mouse model and application of model |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130142894A1 (en) * | 2011-11-16 | 2013-06-06 | Bimini Llc | Health supplement compositions for companion animals and methods of using the same |
| CN103356796A (en) * | 2013-06-24 | 2013-10-23 | 广州中医药大学 | Blood stasis removing particles and preparation method thereof |
-
2015
- 2015-11-04 CN CN201510742181.XA patent/CN105194072A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130142894A1 (en) * | 2011-11-16 | 2013-06-06 | Bimini Llc | Health supplement compositions for companion animals and methods of using the same |
| CN103356796A (en) * | 2013-06-24 | 2013-10-23 | 广州中医药大学 | Blood stasis removing particles and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 李志刚: "莫西沙星治疗肺部感染患者疗效及血浆D-二聚体的变化", 《实用诊断与治疗杂志》 * |
| 洪旭初等: "血府逐瘀汤配合西药治疗血瘀型慢性阻塞性肺疾病急性加重期临床观察", 《广西中医药大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114514912A (en) * | 2022-03-10 | 2022-05-20 | 北京中医药大学第三附属医院 | Construction method of LPS-induced chronic lung injury stagnant heat internal accumulation syndrome mouse model and application of model |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN106138668A (en) | A kind of Chinese medicine composition treating COPD and preparation method thereof | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN105194072A (en) | Traditional Chinese medicine composition with efficacy of assisting in treatment of pulmonary infection | |
| CN103041251A (en) | Traditional Chinese medicine composition for treating chronic bronchitis | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN102641350B (en) | Lung-warming panting-calming granule and preparation process thereof | |
| CN114588242B (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN107050340B (en) | Traditional Chinese medicine composition for treating necrotizing lymphadenitis and application thereof | |
| CN1337252A (en) | Chinese medicine for treating chronic bronchitis | |
| CN103341094B (en) | Preparation method of powder for treating vulva squamous epithelial cell hyperplasia | |
| CN104721388A (en) | Traditional Chinese medicine composition for treating severe influenza of high risk groups as well as preparation method and application of traditional Chinese medicine composition | |
| CN106389843A (en) | Traditional Chinese medicinal composition used for improving dry mouth and dry throat, and preparation method and application thereof | |
| CN105902943A (en) | Medicine composition for treating wind heat cough of children | |
| Liu et al. | Treatment with Yiqi Bushen Koufuye combined with chemotherapy for preventing postoperative metastasis of stomach cancer—a clinical observation of 28 cases | |
| CN104940851A (en) | Asarum traditional Chinese medicine composition for treating cold asthma | |
| CN105168888B (en) | It is a kind of for treating the Chinese medicine composition and application thereof of fash caused by molecular targeted agents | |
| CN116270872A (en) | Traditional Chinese medicine composition for treating chronic kidney disease | |
| CN104971298A (en) | Pyrrosia leaf traditional Chinese medicine composition for treating phlegm-heat lung obstructing type asthma | |
| CN108619373A (en) | The new application of shellfish tangerine cough syrup | |
| CN117122661A (en) | Traditional Chinese medicine composition and preparation for treating chronic cholecystitis liver Yu Dan heat syndrome and application thereof | |
| CN113134063A (en) | Traditional Chinese medicine composition for treating aphtha | |
| CN103301354B (en) | Preparation method of powder for treating infantile vaginitis | |
| CN114432381A (en) | Traditional Chinese medicine composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151230 |